Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.50 |
| ▸ | HTR3B | O95264 | 5/20 | 0.50 |
| ▸ | HTR3A | P46098 | 5/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17265646 | 0.87 | MAPT (0.52) | MAPTRECQLALDH1A1HTTKDM4E | |
| SCHEMBL24196401 | 0.86 | MAPT (0.56) | MAPTRECQLADRB1HTR3EHTR3B | |
| Tert-Butyl Formate SCHEMBL27945027 | 0.84 | MAPT (0.43) | MAPTRECQLADRB1HTR3EHTR3B | |
| SCHEMBL478208 | 0.83 | ADRB1 (0.57) | MAPTADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL22289269 | 0.83 | ALDH1A1 (0.61) | MAPTRECQLALDH1A1THRBTP53 | |
| SCHEMBL3376365 | 0.83 | ALDH1A1 (0.56) | MAPTRECQLALDH1A1THRBTP53 | |
| SCHEMBL8071214 | 0.83 | MAPT (0.61) | MAPTRECQLADRB1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL30892475 | 0.81 | ADRB1 (0.55) | MAPTADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL28512966 | 0.81 | ADRB1 (0.55) | MAPTADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL1127082 | 0.81 | ALDH1A1 (0.65) | MAPTRECQLALDH1A1THRBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| CN-105960404-B | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-105960404-A | Inhibitors of bruton's tyrosine kinase | 药品循环有限责任公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-2665727-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097684-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8115011-B2 | (S)-3-{5-[(1-Pyridin-2-yl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-ylamino}-pyrrolidine-1-carboxylic acid ethyl ester; obesity, type II diabetes mellitus and metabolic syndrome | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8058299-B2 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| CN-101835757-A | Diacylglycerol acyltransferase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885RECQL 2629/4885ADRB1 1161/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885RECQL 2629/4885ADRB1 1161/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885RECQL 2629/4885ADRB1 1161/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | MAPT 3561/4885RECQL 2629/4885ADRB1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.